# Study of AT-527 in Subjects With Normal and Impaired Renal Function

> **NCT05618314** · PHASE1 · COMPLETED · sponsor: **Atea Pharmaceuticals, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Healthy Volunteer
- Renal Impairment

## Interventions

- **DRUG:** AT-527
- **DRUG:** AT-527
- **DRUG:** AT-527 and Probenecid

## Key facts

- **NCT ID:** NCT05618314
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-17
- **Primary completion:** 2024-06-15
- **Final completion:** 2024-06-15
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05618314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05618314, "Study of AT-527 in Subjects With Normal and Impaired Renal Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05618314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*